Analysis of response of severe eosinophilic asthmatic patients to benralizumab.

Autor:	Miralles-López JC; Allergy Department, University General Hospital Reina Sofia, Murcia, Spain., Andújar-Espinosa R; Pulmonology Department. University Clinic Hospital Virgen de la Arrixaca, Murcia, Spain., Bravo-Gutiérrez FJ; Pulmonology Department, University General Hospital Santa Lucia, Cartagena, Murcia, Spain., Castilla-Martínez M; Pulmonology Department, University General Hospital Los Arcos, San Javier, Murcia, Spain., Flores-Martín I; Allergy Department, University General Hospital Santa Lucia, Cartagena, Murcia, Spain., Alemany-Francés ML; Pulmonology Department, University General Hospital Morales Meseguer, Murcia, Spain., Pajarón-Fernández MJ; Allergy Department, Hospital de la Vega Lorenzo Guirao, Cieza, Murcia, Spain., Mora-González A; Allergy Department, University General Hospital Morales Meseguer, Murcia, Spain., Cabrejos-Perotti S; Allergy Department, Hospital Rafael Méndez, Lorca, Murcia, Spain., El-Molaka Z; Pulmonology Department, Hospital Rafael Méndez, Lorca, Murcia, Spain., Meseguer-Arce J; Allergy Department, University Clinic Hospital Virgen de la Arrixaca, Murcia, Spain., Avilés-Inglés MJ; Pulmonology Department, University General Hospital Reina Sofia, Murcia, Spain., Valverde-Molina J; Paediatrics Department, University General Hospital Santa Lucia, Cartagena, Murcia, Spain; jvm.neumoped@gmail.com., Pérez-Fernández V; Department of Public Health Sciences, University of Murcia School of Medicine, Murcia, Spain.
Jazyk:	angličtina
Zdroj:	Allergologia et immunopathologia [Allergol Immunopathol (Madr)] 2022 Nov 01; Vol. 50 (6), pp. 163-168. Date of Electronic Publication: 2022 Nov 01 (Print Publication: 2022).
DOI:	10.15586/aei.v50i6.704
Abstrakt:	Introduction: Clinical trials and real-life studies have been published showing effectiveness of benralizumab in severe eosinophilic asthmatic patients. The aim of the present study is to describe super-responders to benralizumab in a series of 79 patients who completed at least 1 year of treatment, and to compare super-responders with non super-responders. Methods: This is a multicenter study of the Register of Severe Asthma of the Region of Murcia (RE-ASGRAMUR) Group performed in eight hospitals under the conditions of routine clinical practice. Patients with zero exacerbations and no oral corticosteroid therapy for asthma were considered super-responders. We analyzed clinical, functional, and inflammatory parameters of selected patients. Results: In all, 50 of the 79 patients (63%) met the super-responder criteria. In addition, 36% of the patients (26/71) were considered as complete responders to treatment (super--responder + Asthma Control Test [ACT] ≥ 20 + forced expiratory volume in 1 s [FEV1] ≥ 80%). The super--responders were significantly older in age (P = 0.0029), had higher eosinophils count (P = 0.0423), higher proportion of nasal polyps (P = 0.036), and they had less severe disease at baseline. After 1 year of treatment, the super-responders had higher levels of ACT questionnaire (23 vs 19, P = 0.0007) and better percentage of FEV1 (83 vs 75, P = 0.0359). Conclusion: Almost two of the three patients treated with benralizumab were super--responders after 1 year of treatment and 36% had a complete response. Super-responders were associated with older age, higher eosinophils count, had nasal polyposis as comorbidity, and had less severe disease at baseline. This data illustrated the good real-life response of patients with severe eosinophilic asthma to the treatment with benralizumab. Competing Interests: Juan Carlos Miralles-López received consultancy fees from Chiesi and speaker fees from Novartis, GSK, Astra Zeneca, Sanofi, and Chiesi. Rubén Espinosa-Andújar received speaker fees from Novartis, GSK, Astra-Zeneca, Sanofi, and Chiesi. Francisco Javier Bravo-Gutiérrez received speaker fees from Novartis, Ferrer, GSK, Astra-Zeneca, Sanofi, and Chiesi. Manuel Castilla-Martínez received consultancy fees from GSK and Astra Zeneca and speaker fees from Novartis, GSK, Astra-Zeneca, Sanofi, and Chiesi. Isabel María Flores-Martín received speaker fees from Novartis, GSK, and Sanofi. María Loreto Alemany-Francés received speaker fees from Novartis, GSK, Astra-Zeneca, and Chiesi. Manuel José Pajarón-Fernández received speaker fees from GSK. Sheila Cabrejos-Perotti received speaker fees from Sanofi. Zouhair El-Molaka received speaker fees from Astra-Zeneca, Teva, and GSK. José Meseguer-Arce received speaker fees from GSK. María Jesús Avilés-Inglés received speaker fees from Chiesi. José Valverde-Molina received consultancy fees from Astra-Zeneca; speaker fees from Novartis, GSK, Astra-Zeneca, Sanofi, Teva, Orion Pharma; and fees for advisory board from GSK and Novartis. Finally, Ana Mora-González and Virginia Pérez-Fernández had no conflicts of interest to declare.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu